Rocket Lab's Neutron Just Slipped Again. Here's the Only Date That Still Matters for Shareholders.

Rocket Lab's Neutron debut could slip to 2027 after management shifted its target to delivering the rocket to the launch pad in Q4 2026, contributing to a 24% decline in RKLB shares over the past two weeks. The more consequential catalyst is its planned $8 billion acquisition of Iridium Communications, expected to close around mid-2027, which would add roughly $884 million of annual revenue at 72% gross margins. Iridium is forecast to generate more than $135 million in 2027 GAAP profit and over $313 million in free cash flow, potentially making Rocket Lab profitable and free-cash-flow positive earlier than Wall Street expected.

Analysis

The central valuation issue is not whether acquired cash flow can arithmetically offset RKLB's current burn, but the price and financing required to obtain it. At an $8B enterprise value, IRDM is likely being acquired at a premium multiple of its mature, contracted cash flow; if RKLB uses substantial equity, the per-share benefit could be diluted away, while debt financing would replace operating-risk exposure with refinancing and covenant risk. The market should value the transaction as a leveraged telecom acquisition until a definitive merger agreement discloses consideration mix, assumed debt, breakup terms, and pro forma leverage—not as an automatic profitability rerating.

IRDM's standalone holders gain a potential bid floor, but their upside is capped near the implied consideration unless a competing bidder emerges. The less obvious loser is RKLB's strategic flexibility: a large cash commitment could constrain spending on Neutron, space-systems M&A, and factory ramp, precisely when launch-development costs and schedule risk are highest. A later Neutron debut also weakens the near-term synergy case because Iridium's current constellation economics are not meaningfully dependent on new launch capacity; claimed vertical-integration benefits therefore belong primarily to the next replenishment cycle, not the first 12 months after closing.

Near term, RKLB can remain volatile around schedule updates and financing rumors; the 1-3 month catalyst is definitive deal documentation rather than another aspirational launch milestone. Over 6-18 months, the key test is whether combined free cash flow remains positive after interest expense, integration costs, capex, and Neutron development—not reported GAAP profitability. Consensus appears too willing to capitalize IRDM's cash generation at face value while overlooking that a premium-priced acquisition can be value-destructive even if it makes consolidated earnings positive.

Key Decisions for Investors

• Do not add directional RKLB exposure solely on the projected cash-flow crossover. Establish a diligence alert for definitive consideration mix and pro forma net debt/EBITDA; consider a long only if equity dilution is below 15% and management demonstrates post-close FCF positivity after interest and development capex.
• For existing RKLB longs, reduce exposure into any financing-driven rally and retain upside through a defined-risk call spread dated after expected merger documentation, rather than unhedged stock. Thesis is falsified by another Neutron schedule slip, an equity raise at a material discount, or guidance showing incremental cash burn through 2028.
• Maintain IRDM as a merger-arbitrage watch rather than a fundamental long: buy only if the discount to disclosed cash consideration provides adequate annualized spread after assigning meaningful closing risk. Exit if regulatory review, financing commitments, or RKLB shareholder support deteriorate.
• Potential pair after terms are announced: long IRDM / short RKLB in a deal-risk basket if RKLB trades as though acquisition financing is immaterial. Cover the short if the consideration is predominantly stock at a favorable fixed exchange ratio or if independently financed synergies exceed the incremental interest and integration burden.